How to Read a BCR-ABL Quantitative Report

A BCR-ABL quantitative report tells you how much leukemia-related genetic material remains in your blood, expressed as a percentage on a standardized measuring stick called the International Scale (IS). The number you care about most is the BCR-ABL1 ratio, usually written as something like “BCR-ABL1 IS = 0.05%.” Lower is better, and the trend over several reports matters far more than any single result. But the report contains other elements that affect how confidently you can interpret that central number, and understanding them can save you from unnecessary worry or, occasionally, flag a problem your care team needs to act on.

What the BCR-ABL1 Ratio Actually Represents

Chronic myeloid leukemia starts when pieces of two chromosomes swap places, creating an abnormal gene called BCR-ABL1. That gene produces a protein with overactive signaling that drives white blood cells to multiply out of control. In the vast majority of cases, the fusion produces one of two closely related messenger RNA transcripts, known as b3a2 or b2a2, both of which code for the same troublesome protein.¹ Your quantitative report measures how many copies of that abnormal transcript are present in a blood sample, relative to copies of a normal “housekeeping” gene that acts as an internal yardstick.

The lab runs a test called RT-qPCR, which amplifies tiny amounts of RNA so they can be counted.² The result is a ratio: BCR-ABL1 copies divided by control gene copies, multiplied by 100 to give a percentage. A report reading 1% means that for every 100 copies of the control gene detected, there was one copy of BCR-ABL1. A reading of 0.001% means the lab found one copy for every 100,000 control gene copies. That is a thousand-fold difference in residual disease, which is why small-looking shifts in these percentages can carry real clinical weight.

The International Scale and Why Your Report Uses It

Not every lab uses the same equipment, reagents, or calculation method. Left to their own devices, two labs testing the same blood sample could easily report different numbers. The International Scale was created to fix this. Each lab applies a conversion factor so that its raw result lines up with an agreed-upon reference point: 100% IS corresponds roughly to the median BCR-ABL1 level in a group of untreated CML patients from an early landmark trial. Every result your lab reports “on IS” has been adjusted so it can be compared to results from other labs and to the treatment milestones your doctor uses.

Adoption of the IS made a measurable difference. Proficiency testing data spanning 15 years showed that as IS adoption climbed from around 8% of participating labs in 2009 to over 99% by 2019, the scatter between labs dropped dramatically.³ Still, some variability persists. International quality-assessment programs have found that different methods of converting raw data to the IS can produce consistently different median results, meaning two IS-reported numbers from two labs may not be perfectly interchangeable.⁴ The practical takeaway: whenever possible, have your monitoring done at the same lab each time. If you do switch labs, mention it to your doctor so that any apparent jump or dip can be interpreted with that context.

Response Milestones and What the Numbers Mean for You

Your care team translates the BCR-ABL1 IS percentage into named response levels. These milestones guide treatment decisions and are the vocabulary you will hear most often in clinic visits.

MMR (MR3): BCR-ABL1 ≤ 0.1% IS. “Major molecular response.” This is the primary target, roughly a thousand-fold reduction from the untreated baseline. Reaching and staying at MMR is associated with excellent long-term outcomes.
MR4: BCR-ABL1 < 0.01% IS. A deeper response, sometimes called "deep molecular response" (DMR). This level is essential for patients who hope to eventually stop therapy.[mfn]PubMed Central. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?[/mfn]
MR4.5: BCR-ABL1 ≤ 0.0032% IS. Even deeper suppression, confirmed in studies as a meaningful prognostic threshold.⁵
MR5: BCR-ABL1 ≤ 0.001% IS. The deepest routinely reported level. Achieving this consistently is rare and not required for most clinical decisions.

European LeukemiaNet (ELN) guidelines also set time-based benchmarks during the first year of treatment: your BCR-ABL1 IS should be at or below 10% by three months, at or below 1% by six months, and at or below 0.1% (MMR) by twelve months. Responses are categorized as optimal, warning, or failure based on where you land relative to those thresholds.⁶ If your report arrives and shows you are above the expected milestone for your time point, that does not automatically mean treatment has failed, but your doctor will want to investigate.

The Control Gene Count and Test Sensitivity

Toward the bottom of most reports, you will see a line noting the number of control gene copies detected, often labeled “ABL1 copies” or “GUSB copies.” This number tells you how sensitive the test was for that particular sample. Think of it like the resolution of a photograph: more control gene copies mean finer resolution, and the lab can confidently call deeper levels of response.

Specific thresholds apply. For a result to qualify as MR4 when BCR-ABL1 is undetectable, the lab needs to have found at least 10,000 ABL1 copies (or about 24,000 GUSB copies). For MR4.5, the threshold rises to 32,000 ABL1 copies; for MR5, at least 100,000.⁷ If your report says “BCR-ABL1 undetectable” but the control gene count is low, the test simply was not sensitive enough to confirm deep molecular response. The report might say something like “undetectable, sensitivity MR3 only.” That does not mean your disease has progressed; it means the sample could not tell you whether you are in MR4 or deeper. A repeat test with a better-quality sample can usually resolve it.

Why would a control gene count come in low? The most common reason is RNA degradation from delays in shipping or processing the blood sample. Research has shown that unstabilized blood processed on the day of collection yields reliable RNA, but a delay of even a couple of days at room temperature causes a dramatic loss of intact RNA and unreliable quantitative results.⁸ If you live far from the testing lab and your results seem oddly inconsistent, ask whether your blood draw site uses a stabilization tube or ships overnight on ice.

Fluctuations Are Normal, Trends Are What Matter

One of the most anxiety-inducing experiences is seeing your BCR-ABL1 number tick upward after months of decline. Before assuming the worst, know that fluctuations in the BCR-ABL1 ratio are extremely common, even in patients who remain in solid remission. Research tracking patients in major and complete molecular response found that single-point variations happen frequently and can stem from inconsistencies in the blood draw, day-to-day biological variation, minor differences in lab processing, or a stretch of imperfect medication adherence.⁹ Most of those patients stayed in cytogenetic remission despite the blips, and the variations did not predict treatment failure.

The clinical guidance is clear: do not make treatment decisions based on a single result. BCR-ABL1 transcript numbers follow one of four broad patterns over time: steadily declining, stably undetectable, plateaued at a steady level, or rising. It is the pattern that matters. A one-time uptick from 0.01% to 0.05% followed by a return to 0.01% is noise. A steady climb across three or more consecutive tests is a signal worth investigating.¹⁰ If you find yourself worrying about an individual result, ask your care team to plot your values on a graph. Seeing the trajectory laid out visually often makes it obvious that a single blip sits well within the noise band.

Possible reasons for a genuinely rising trend, beyond disease progression, include drug-drug interactions that lower the effective level of your tyrosine kinase inhibitor (TKI), food interactions (grapefruit juice, for instance, can alter drug metabolism), and nonadherence. Your care team will typically rule out these factors before considering a therapy change.

When “Undetectable” Appears on Your Report

Seeing “BCR-ABL1 not detected” can feel like the finish line, but it requires careful reading. “Not detected” is not the same as “cured.” It means the test could not find any BCR-ABL1 transcripts in the sample at the sensitivity the test achieved. The disease may still be present at levels below the test’s detection limit. That is why the control gene count, described earlier, matters so much when the result is undetectable: it determines whether you can claim MR4, MR4.5, or MR5.

Sustained deep molecular response, maintained for at least a year, is the clinical benchmark that opens the door to considering treatment-free remission (TFR), which means stopping your TKI under close monitoring to see whether the disease stays suppressed on its own. Research has defined sustained MR4 as maintaining BCR-ABL1 below 0.01% IS for at least 12 months.¹¹ In a trial of patients who stopped dasatinib after sustained deep response, about 46% remained in treatment-free remission at two years.¹² For those who do lose response after stopping, restarting the same drug almost always brings it back. Monitoring after discontinuation is typically monthly for the first three months, then quarterly for a year, and then every six months, with the trigger for restarting therapy being loss of MMR.¹³

Mutation Testing and What It Adds to the Picture

If your BCR-ABL1 levels are rising despite good adherence, your report or a follow-up order may include mutation analysis of the BCR-ABL1 kinase domain. The kinase domain is the part of the abnormal protein that your TKI is designed to block. Mutations in this region can change the shape of the protein enough that the drug no longer fits, rendering it ineffective. Screening for these mutations is now routine whenever a patient meets criteria for “warning” or “failure” response.¹⁴

The most infamous mutation is T315I, sometimes called the “gatekeeper” mutation because it sits at a critical contact point in the protein. T315I confers resistance to most first- and second-generation TKIs. In a matched analysis of patients who developed imatinib resistance, those carrying T315I had significantly shorter overall survival compared with resistant patients without it.¹⁵ The third-generation drug ponatinib and the newer allosteric inhibitor asciminib were specifically developed to address T315I, so identifying this mutation early changes the treatment plan in a concrete way.

Traditionally, mutation testing is performed by Sanger sequencing, but that method can miss mutations present at low levels. Next-generation sequencing (NGS) offers greater sensitivity and can distinguish whether a patient carries one mutation or several at the same time.¹⁶ Research using NGS at the point of therapy switch found that in over 40% of patients, the resistance mutation that later caused relapse was already detectable at low levels in the sample taken at the time of the switch, and every one of those low-level mutations expanded when the patient received a drug to which the mutation was insensitive.¹⁷ Whether routine use of NGS-level sensitivity actually improves long-term outcomes is still being studied, but the technology is increasingly available.¹⁸

Atypical Transcripts and the Risk of False Negatives

Most CML patients carry one of the two standard BCR-ABL1 transcript types, and the routine PCR test is designed to detect them. But a small fraction of patients produce atypical fusion transcripts with breakpoints in unusual locations. If the lab’s test primers are not positioned to catch these variants, the result can come back as “not detected” even though the disease is present and active. Case reports have documented situations in which a negative PCR result would have been misinterpreted as molecular remission had it not been cross-checked against cytogenetic or FISH testing at diagnosis.¹⁹

Expert recommendations stress that characterizing the exact transcript type at diagnosis is essential to avoid false-negative monitoring results down the road.²⁰ If you carry an atypical transcript, your lab needs to use a customized assay or a different monitoring strategy, such as periodic FISH or cytogenetics, alongside or instead of standard PCR. This is rare enough that most patients never encounter it, but if your initial workup mentioned an unusual breakpoint, it is worth confirming that your monitoring lab is aware.

Digital PCR and Emerging Technologies

Standard RT-qPCR has served CML monitoring well, but a newer method called digital PCR (dPCR) is starting to appear in some labs. Instead of measuring fluorescence intensity in a tube of amplified material, digital PCR partitions the sample into thousands of individual droplets, each containing zero or one target molecule, and counts them directly. This approach can improve sensitivity and reduce the variability that comes from comparing a target signal to a standard curve.

Head-to-head comparisons have shown that digital PCR reclassifies a substantial proportion of patients into different molecular response groups compared with standard methods, generally by detecting residual disease that standard PCR calls undetectable. In one study, about 21% of samples reported as undetectable by standard PCR turned up positive on digital PCR.²¹ Another study found that while dPCR’s detection limit was above three BCR-ABL1 copies and its resulting sensitivity was around MR4, it still categorized more than half of patients differently from the GeneXpert platform, suggesting improved detection in the deep-response range.²²

For most patients today, standard RT-qPCR remains the backbone of monitoring, and treatment guidelines are calibrated to it. But if your report comes from a lab using digital PCR, the numbers may not be directly comparable to results from a lab using standard methods. Bring this up with your care team if you are switching between technologies or between labs that use different platforms. As with the IS conversion issue, consistency is king: the most interpretable data comes from having every sample run the same way.

Practical Tips for Making Sense of Your Results

Keeping a personal log of your BCR-ABL1 results over time is one of the most useful things you can do. A simple spreadsheet with the date, the IS percentage, and the control gene count is enough. Plotting those values on a chart, even roughly, turns an intimidating list of decimals into a visual story that makes trends obvious. Clinicians have compared this practice to tracking blood pressure or blood sugar readings: the individual number matters less than the direction it is heading.¹⁰

When reviewing a new report, consider these questions before calling your doctor in a panic:

Is it on IS? If the result is not converted to the International Scale, it cannot be compared to standard milestones.
Same lab as last time? A lab switch can introduce apparent shifts that are technical, not biological.
Control gene count adequate? A low count means the sensitivity ceiling was low, and an “undetectable” result may not mean what you think.
One-time blip or trend? A single uptick surrounded by stable or declining values is almost always noise.
Any recent adherence gaps? Even a few missed doses can cause a temporary bump in transcript levels that resolves once adherence resumes.

If you see a result that confuses you, write your questions down before your next appointment. Understanding what the numbers can and cannot tell you transforms the report from a source of anxiety into a genuinely useful tool for managing your health over the long haul.